Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.785 USD | +2.01% | +4.92% | +10.80% |
04-05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
04-04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Business Summary
Number of employees: 73
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapeutics
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 39 | 100.0 % | 18 | 100.0 % | -53.51% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 30/06/14 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 10/06/18 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Sofia
CTO | Chief Tech/Sci/R&D Officer | 66 | 28/02/15 |
John Naftzger
CMP | Compliance Officer | 57 | 09/07/23 |
Investor Relations Contact | - | 20/09/21 | |
Shannon Briscoe
HRO | Human Resources Officer | - | 30/06/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 30/11/14 | |
James Meyers
BRD | Director/Board Member | 58 | 22/10/18 |
Daniel Burgess
BRD | Director/Board Member | 62 | 22/03/17 |
Keith Manchester
BRD | Director/Board Member | 55 | 03/03/15 |
Frank Torti
CHM | Chairman | 45 | 25/11/18 |
Chief Executive Officer | 49 | 30/06/14 | |
Director/Board Member | 55 | 11/07/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 180,174,930 | 138,114,650 ( 76.66 %) | 0 | 76.66 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.80% | 492M | |
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-13.61% | 15.36B | |
-8.82% | 11.95B | |
-15.69% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- ABUS Stock
- Company Arbutus Biopharma Corporation